How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

29,105 results for

Alcoholic Hepatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

29081. Prazosin Alcohol Dependence IVR Study

, decreases alcohol consumption and/or the subjective experience of alcohol craving in individuals without post-traumatic stress disorder (PTSD) who are seeking treatment for alcohol dependence. The study hypotheses are: (1) Subjects treated with prazosin will report fewer drinking days and fewer drinks per drinking day than subjects treated with placebo, (2) subjects treated with prazosin will report decreased craving for alcohol as compared to subjects in the placebo condition, and (3) prazosin (...) informed consent no planned absences during six week active treatment period that would prevent weekly check-in wiht the study psychiatrist English fluency Exclusion Criteria: Score 50 or greater on the PTSD Check List which suggests a current diagnosis of PTSD Psychiatric disorder requiring any medication other than anti-depressants Current diagnosis of opiate dependence or abuse, chronic treatment with any opiate-containing medications during the previous month, or urine positive for opioids

2005 Clinical Trials

29082. Topiramate for Alcohol and Cocaine Dependence

Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Male and females, 18 years or older. Meets DSM(Diagnostic and Statistical Manual)-IV criteria for current diagnoses of cocaine and alcohol dependence, determined by the SCID (Structured Clinical Interview for the DSM)-IV. In the past 30 days, used no less than $200-worth of cocaine and meets the following drinking criteria as measured by the Timeline (...) Topiramate for Alcohol and Cocaine Dependence Topiramate for Alcohol and Cocaine Dependence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topiramate for Alcohol and Cocaine Dependence (TOP2) The safety

2005 Clinical Trials

29083. Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence

of Pennsylvania Collaborator: National Institute on Drug Abuse (NIDA) Information provided by (Responsible Party): Kyle Kampman, University of Pennsylvania Study Details Study Description Go to Brief Summary: The purpose of this study is to see whether naltrexone is safe and useful in preventing alcohol relapse, as well as in decreasing craving for alcohol in people with a diagnosis of alcohol and cocaine dependence. Naltrexone is approved by the Food and Drug Administration (FDA) for the treatment of alcohol (...) dependence. However, the medication was not approved as yet at the dosage we will use in this study. The dosage we will use for the study (150 mg), is greater than the recommended dosage from the Physician's Desk Reference (50mg). Unlike other medicines (like Antabuse) useful in the treatment of alcohol dependence, naltrexone will not make you sick if you drink alcohol. Rather, people who are taking this medication have reported that it helps decrease the pleasure associated with drinking for them

2005 Clinical Trials

29084. The role of iNOS in alcohol-dependent hepatotoxicity and mitochondrial dysfunction in mice. (Abstract)

The role of iNOS in alcohol-dependent hepatotoxicity and mitochondrial dysfunction in mice. Nitric oxide (NO) is now known to control both mitochondrial respiration and organelle biogenesis. Under conditions of ethanol-dependent hepatic dysfunction, steatosis is increased, and this is associated with increased expression of inducible nitric oxide synthase (iNOS). We have previously shown that after chronic exposure to ethanol, the sensitivity of mitochondrial respiration to inhibition (...) ethanol showed no change in the sensitivity to NO-dependent inhibition of respiration. In conclusion, the hepatic response to chronic alcohol-dependent cytotoxicity involves a change in mitochondrial function dependent on the induction of iNOS.Copyright 2004 American Association for the Study of Liver Diseases

2004 Hepatology

29085. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. (Abstract)

[31%]) groups (p=0.12). Cumulative abstinence duration was about twofold higher in patients allocated baclofen than in those assigned placebo (mean 62.8 [SE 5.4] vs 30.8 [5.5] days; p=0.001). No hepatic side-effects were recorded.Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis. The drug is well tolerated and could have an important role in treatment of these individuals. (...) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Intervention to achieve alcohol abstinence represents the most effective treatment for alcohol-dependent patients with liver cirrhosis; however, anticraving drugs might worsen liver disease. We aimed to investigate the effectiveness and safety of baclofen in achieving and maintaining alcohol abstinence in patients with liver

2007 Lancet Controlled trial quality: predicted high

29086. Pentoxifylline in Severe Alcoholic Hepatitis: Pentoxifylline in alcoholic hepatitis

of hepatorenal syndrome. A 2009 Cochrane Review concluded that insufficient evidence exists to demonstrate that pentoxifylline reduces mortality. The 2015 trial randomized patients to pentoxifylline, prednisolone, or placebo. There was no mortality benefit with pentoxifylline, but prednisolone was associated with a non-significant trend towards mortality reduction. Guidelines AASLD/ACG Alcoholic Liver Disease (2010, adapted) For patients with alcoholic hepatitis: Alcohol abstinence counseling (class I, level (...) : 1992-1997 Analysis: intention-to-treat Population Baseline characteristics Demographics: Male: 71% Age: 42.4 years Medical data: Days of treatment: 21.5 Days before randomization: 3.9 Previous decompensation: 24% Hepatic encephalopathy: 8% Creatinine above 2.4 mg/dL: 6.1% Ascites: 76% Edema: 59% Varices: 80% Splenomegaly: 21% Fever (above 100 0 F): 13% Palpable hepatomegally Hepatic bruit: 59% Inclusion Criteria History of heavy alcohol abuse Admission for acute alcoholic hepatitis Jaundice One

2000 Wiki Journal Club

29087. An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder

: Bipolar affective disorder is a medical illness with substantial morbidity and mortality. Further fueling the severity of this illness is the substantial co-occurrence with substance abuse that together poses an enormous public health problem. This study will evaluate the efficacy of divaproex sodium (DVPX) vs. olanzapine (ZYP) vs. for alcohol relapse prevention and secondary mood stabilization. Bipolar patients who are actively drinking will be randomized to either Depakote ER ® (flexible dose (...) stability. The primary outcome measure will be alcohol abuse relapse which will be defined, a priori, as 5 drinks in a 24 hour period. Patients who have a relapse as such defined will be terminated from the study. Secondary alcohol outcome measures (i.e. number of drinking days, % drinking days per month, standard drinks per drinking occasion, craving) will be assessed through the time-line follow-back method. Secondary outcome measures of mood stabilization (major mood relapse and adjunctive medication

2005 Clinical Trials

29088. Acetaminophen-Induced Hepatotoxicity in Chronic Alcohol Abusers

Acetaminophen-Induced Hepatotoxicity in Chronic Alcohol Abusers Acetaminophen-Induced Hepatotoxicity in Chronic Alcohol Abusers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Acetaminophen-Induced (...) Hepatotoxicity in Chronic Alcohol Abusers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00137059 Recruitment Status : Completed First Posted : August 29, 2005 Last Update Posted : December 13, 2005 Sponsor: Queen's University Information provided by: Queen's University Study Details Study Description Go

2005 Clinical Trials

29089. Should we use carbohydrate deficient transferrin as a marker for alcohol abusers? Full Text available with Trip Pro

Should we use carbohydrate deficient transferrin as a marker for alcohol abusers? Carbohydrate deficient transferrin (CDT) is one of the conventional markers for chronic alcohol consumption, is used by researchers and clinicians. A number of enzymes are affected by ethanol intake. The induction or inhibition of sialyl transferase and plasma sialidase may be involved in the CDT level elevation. An alteration of protein transport during post-translational modification could be a primary mechanism (...) in the impairment of protein metabolism associated with chronic alcohol abuse. Transferrin being a steroid responsive protein, sex-based hormonal variations might contribute to the lower sensitivity of CDT. Varying hormonal statuses such as pregnancy, use of contraceptives, menopause/ menstrual cycle can alter iron homeostasis in women. CDT levels are markedly affected by iron homeostasis. Several CDT assay methods appeared promising, but it is not readily apparent which technique is the most accurate. Moreover

2004 Indian Journal of Clinical Biochemistry

29090. Naltrexone Treatment of Alcohol Abuse in Schizophrenia

have alcohol abuse or dependence. We will test hypothesis 1: Naltrexone will be more effective than placebo in reducing alcohol use. Our primary outcome measure will be the number of drinking days over the course of the treatment trial. To test naltrexone's efficacy in reducing psychiatric symptom severity and medical utilization by reducing alcohol use. We will test hypothesis 2: Patients responding to naltrexone by reducing alcohol use will also show reductions in severity of psychiatric symptoms (...) doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 69 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Males or females, age 18 to 69, with a DSM-IV diagnosis of Schizophrenia or Schizoaffective Disorder; DSM-IV diagnosis of Alcohol Abuse or Alcohol Dependence; Level of Drinking: At least four days

2005 Clinical Trials

29091. Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. Full Text available with Trip Pro

Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease. More than 70% of alcohol is consumed by 10% of the population in the United States. Implicit in this statistic is that tremendous variation in the pattern of drinking (quantity, frequency, and duration) exists among alcohol consumers. Individuals who are binge or chronic drinkers will have different health outcomes than social drinkers. Therefore, knowing the pattern of drinking will shed light (...) -dependent and to susceptibility to alcohol-induced liver damage. Chronic alcohol consumption induces cytochrome P450 2E1, a microsomal enzyme that metabolizes alcohol at high concentrations and also metabolizes medications such as acetaminophen and protease inhibitors. Alcohol metabolism changes the redox state of the liver, which leads to alterations in hepatic lipid, carbohydrate, protein, lactate, and uric acid metabolism. The quantity and frequency of alcohol consumption severely impact the liver

2007 Hepatology

29092. Long-term outcome of liver resection for hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol abuse. (Abstract)

Long-term outcome of liver resection for hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol abuse. Hepatocellular carcinoma (HCC) occurs primarily in cirrhotic liver, with less than 10% occurring in normal liver parenchyma. Limited studies have described the outcome of liver resection in strictly normal liver parenchyma with no cirrhosis, fibrosis, underlying viral hepatitis, alcohol abuse, or dysmetabolic syndrome.Between January 1986 and 2005

2008 World Journal of Surgery

29093. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. (Abstract)

Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. To explore the relationship of HIV, hepatitis C (HCV), and alcohol abuse/dependence to risk for hepatocellular carcinoma and non-Hodgkin's lymphoma (NHL).Male veterans (n = 14,018) with a first HIV diagnosis in the Veterans Affairs Healthcare System from October 1997 to September 2004; and 28,036 age-, race-, sex-, and location-matched HIV-negative veterans were identified. We (...) examined the incidence of hepatocellular carcinoma and NHL and presence of HCV and alcohol abuse/dependence using International Classification of Diseases, ninth revision (ICD-9-CM) codes. HIV-positive to HIV-negative incident rate ratios (IRRs) and 95% CIs for the occurrence of hepatocellular carcinoma and NHL were calculated using Poisson regression models.HIV-positive veterans were at greater risk for hepatocellular carcinoma than HIV-negative veterans (IRR = 1.68; 95% CI, 1.02 to 2.77). After

2006 Journal of Clinical Oncology

29094. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. (Abstract)

Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Non-insulin-dependent diabetes mellitus (type 2 diabetes) not responding to dietary treatment alone in patients with non-alcoholic liver cirrhosis is characterized by high postprandial hyperglycaemia. The control of postprandial hyperglycaemia in such patients, is generally achieved by the means of progressively higher doses of insulin (...) +/- 1.7 ng/ml; p < 0.05), whereas the parameters did not change significantly after the placebo. After acarbose treatment a significant increase of intestinal voiding/week (+116% vs. +10%; p < 0.01) and a parallel reduction of blood ammonia levels (-52 +/- 9% vs. -9 +/- 5%; P < 0.01) were observed.The results clearly document the good tolerability and the absence of toxic effects of acarbose on liver, due to the lack of both intestinal absorption and hepatic metabolism of the drug at doses

2001 obesity & metabolism Controlled trial quality: uncertain

29095. Naltrexone Treatment of Alcohol Dependence

below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Meets criteria for current diagnosis of alcohol dependence. Subjects used more than 15 standard alcohol drinks (average)/week with at least 1 day of 5 or more drinks in the past 30 days. Successful completion of medical detoxification. Lives within a commutable distance (...) Naltrexone Treatment of Alcohol Dependence Naltrexone Treatment of Alcohol Dependence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Naltrexone Treatment of Alcohol Dependence The safety and scientific

1999 Clinical Trials

29096. Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)

on Alcohol Abuse and Alcoholism (NIAAA) Information provided by: Yale University Study Details Study Description Go to Brief Summary: This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study. Condition or disease (...) Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Alaska Native having biological Alaska Native ancestry. Meets criteria for alcohol dependence. Prior to entering the study must be abstinent between 3 and 14 days and have a withdrawal assessment. Stable residence to ensure that subjects can be located during the study. Exclusion Criteria: Currently meets criteria for abuse or dependence on substances other than alcohol or nicotine

1999 Clinical Trials

29097. Inhibition of catalase-dependent ethanol metabolism in alcohol dehydrogenase-deficient deermice by fructose. Full Text available with Trip Pro

Inhibition of catalase-dependent ethanol metabolism in alcohol dehydrogenase-deficient deermice by fructose. Hepatic microsomal fractions from ADH (alcohol dehydrogenase)-negative deermice incubated with an NADPH-generating system metabolized butanol and ethanol at rates around 10 nmol/min per mg. In contrast, cytosolic catalase from ADH-negative deermouse liver oxidized ethanol, but not butanol, when incubated with an H2O2-generating system. Thus butanol is oxidized by cytochrome P-450 (...) uptake of about 60 mumol/h per g measured under identical conditions. Rates of ethanol uptake by perfused livers from ADH-positive, but not from ADH-negative, deermice were increased by about 50% by infusion of fructose. Thus it is concluded that the stimulation of hepatic ethanol uptake by fructose is dependent on the presence of ADH. Unexpectedly, fructose decreased rates of ethanol metabolism and H2O2 generation by about 60% in perfused livers from ADH-negative deermice, probably by decreasing

1987 Biochemical Journal

29098. ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

Circuitry [ Time Frame: 14 days (Baseline to Day 14) ] Secondary Outcome Measures : Change From Baseline in Obsessive-Compulsive Drinking Scale (OCDS) Score in Alcohol-dependent Subjects [ Time Frame: 28 days (Baseline to Day 28) ] There are 14 items on the Obsessive Compulsive Drinking Scale (OCDS). The scale is scored from 0 to 40 (units). A score of 0 units indicates no obsession-compulsion with respect to alcohol (best score). A score of 40 units indicates maximum obsession-compulsion with respect (...) to alcohol (worst score). A negative Change from Baseline value indicates an improvement. For scoring methods, see: Anton RF, Moak DH, Latham P (1995), The Obsessive Compulsive Drinking Scale: A self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19:92-9. Change From Baseline in Daily Craving Score in Alcohol-dependent Subjects (Actiwatch Data) [ Time Frame: 28 days (Baseline to Day 28) ] The Actiwatch-Score device (MiniMitter Co.) was used

2007 Clinical Trials

29099. Dose-dependent effects of alcohol on insulin signaling: partial explanation for biphasic alcohol impact on human health. Full Text available with Trip Pro

Dose-dependent effects of alcohol on insulin signaling: partial explanation for biphasic alcohol impact on human health. Routine consumption of alcohol at low doses is associated with decreased risk of acquiring type 2 diabetes, whereas chronic and excessive alcohol consumption increases the risk. Although there is good epidemiologic evidence for these biphasic effects, careful validation of these effects on insulin signaling has not been reported, nor have biological mechanisms underlying (...) these biphasic effects been proposed. In this study, we provide evidence in rats that low-dose alcohol intake (4 g/kg x d) enhances hepatic insulin signaling by suppressing p55gamma (a phosphatidylinositol 3-kinase regulatory subunit isoform) at the posttranscriptional level, leading to the increased association of the phosphatidylinositol 3-kinase catalytic subunit (p110) with insulin receptor substrate-1 (P < 0.05) and subsequent activation of downstream effectors such as Akt, glycogen synthase kinase

2007 Molecular Endocrinology

29100. Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol-abusers. Full Text available with Trip Pro

Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol-abusers. Ethane exhalation was measured in 42 control subjects, 52 patients with various non-alcoholic liver diseases, and 89 alcohol abusers who had been admitted to hospital for alcohol withdrawal and assessment of liver disease (six with normal liver tests, 10 with steatosis with or without fibrosis, six with alcoholic hepatitis, 29 with cirrhosis, 34 with both cirrhosis and alcoholic hepatitis, and four (...) with both cirrhosis and a hepatocellular carcinoma). Ethane exhalation was similar in control subjects and in patients with non-alcoholic liver diseases, but was five times higher in alcohol abusers. Ethane exhalation in alcohol abusers was significantly, but very weakly, correlated with the daily ethanol intake before hospital admission, and the histological score for steatosis, but not with the inflammation or alcoholic hepatitis scores. Ethane exhalation was inversely correlated with the duration

1993 Gut

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>